Stay updated with breaking news from Sybil Tasker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today presented...
Codagenix’s intranasal COVID-19 vaccine has entered Phase 1 clinical trials: with the first volunteers dosed in the UK.
ABC News Turn on desktop notifications for breaking stories about interest? OffOn Phase 1 trials have begun in London for a new nasal vaccine. • 8 min read On Location: April 19, 2021 Catch up on the developing stories making headlines.J. Conrad Williams, Jr./Newsday via Getty Images, FILE LONDON -- Trials have begun in London for the next generation of COVID-19 vaccines with the first dose for a new nasal vaccine being developed by the U.S. company Codagenix having been administered at a quarantine facility in London, it was announced Monday morning. “This vaccine is one of the first of...
Trials have begun in London for the next generation of COVID-19 vaccines with the first dose for a new nasal vaccine being developed by the U.S. company Codagenix.
Green light for UK trial of nasal coronavirus vaccine 15th December 2020 Open Orphan and Codagenix have received approval from the UK’s independent Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct a Phase I study of its COVID-19 vaccine. The study will assess the safety and immunogenicity of a single-dose nasal vaccine candidate COVI-VAC in 48 healthy young adult volunteers. COVI-VAC uses the entire virus in a weakened form, and so has the potential to induce broad antibody, cellular and mucosal immunity with a single intra-nasal dose. According to Open Orphan, it coul...